Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

      The considerable therapeutic potential of human multipotent mesenchymal stromal cells (MSC) has generated markedly increasing interest in a wide variety of biomedical disciplines. However, investigators report studies of MSC using different methods of isolation and expansion, and different approaches to characterizing the cells. Thus it is increasingly difficult to compare and contrast study outcomes, which hinders progress in the field. To begin to address this issue, the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy proposes minimal criteria to define human MSC. First, MSC must be plastic-adherent when maintained in standard culture conditions. Second, MSC must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79α or CD19 and HLA-DR surface molecules. Third, MSC must differentiate to osteoblasts, adipocytes and chondroblasts in vitro. While these criteria will probably require modification as new knowledge unfolds, we believe this minimal set of standard criteria will foster a more uniform characterization of MSC and facilitate the exchange of data among investigators.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Horwitz E.
        • Le B.K.
        • Dominici M.
        • et al.
        Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement.
        Cytotherapy. 2005; 7: 393-395
        • Caplan A.I.
        Mesenchymal stem cells.
        J Orthop Res. 1991; 9: 641-650
        • Zuk P.A.
        • Zhu M.
        • Mizuno H.
        • et al.
        Multilineage cells from human adipose tissue: implications for cell-based therapies.
        Tissue Eng. 2001; 7: 211-228
        • Colter D.C.
        • Class R.
        • Digirolamo C.M.
        • Prockop D.J.
        Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow.
        Proc Natl Acad Sci USA. 2000; 97: 3213-3218
        • Jiang Y.
        • Jahagirdar B.N.
        • Reinhardt R.L.
        • et al.
        Pluripotency of mesenchymal stem cells derived from adult marrow.
        Nature. 2002; 418: 41-49
        • Baksh D.
        • Davies J.E.
        • Zandstra P.W.
        Adult human bone marrow-derived mesenchymal progenitor cells are capable of adhesion-independent survival and expansion.
        Exp Hematol. 2003; 31: 723-732
        • Sabatini F.
        • Petecchia L.
        • Tavian M.
        • et al.
        Human bronchial fibroblasts exhibit a mesenchymal stem cell phenotype and multilineage differentiating potentialities.
        Lab Invest. 2005; 85: 962-971
        • Tropel P.
        • Noel D.
        • Platet N.
        • et al.
        Isolation and characterisation of mesenchymal stem cells from adult mouse bone marrow.
        Exp Cell Res. 2004; 295: 395-406